Form 4: Precigen COO Granted 360,000 Stock Options, Aligning Executive Incentives

Precigen, Inc.'s Chief Operating Officer, Rutul R. Shah, was granted 360,000 options to purchase common stock with an exercise price of $1.37, vesting over a four-year period.

Summary

• Rutul R. Shah, Chief Operating Officer of PRECIGEN, INC. (PGEN), was granted 360,000 options to purchase common stock.
• The transaction date for this grant was May 23, 2025.
• The exercise price for these options is $1.37 per share.
• The options will vest 50% on May 23, 2026, with the remaining 50% vesting in equal monthly installments over the subsequent three years.
• The options have an expiration date of May 23, 2035.
• Following this transaction, Mr. Shah beneficially owns 360,000 derivative securities (options).

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally viewed positively as it aligns management's financial interests with the long-term performance of the company's stock, benefiting shareholders if the company performs well. It's a standard incentive mechanism.

Positives

• The grant of stock options to the Chief Operating Officer aligns executive incentives with long-term shareholder value creation, as the options gain value only if the stock price increases above the exercise price.
• The vesting schedule encourages long-term commitment and retention of key management personnel.

Negatives

• While not an immediate dilution, the exercise of these options in the future could lead to a dilution of existing shareholders' equity.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic outlook, focusing solely on an insider's equity transaction.

Industry Context

The granting of stock options is a common practice in the biotechnology and pharmaceutical industries, particularly for executive compensation. It serves as a key mechanism to attract, retain, and incentivize top talent by linking their compensation directly to the company's stock performance and long-term success.

Comparison to Industry Standards

• The use of stock options as a component of executive compensation is a standard practice across the biotechnology and broader corporate landscape, aligning executive interests with shareholder value.
• The specific size of the grant (360,000 options) and the exercise price ($1.37) would typically be evaluated against peer company compensation packages and the company's stage of development and market capitalization, though such comparative data is not provided in this filing.

Stakeholder Impact

• Shareholders: The grant of options aims to align the Chief Operating Officer's interests with shareholders, potentially leading to improved long-term performance. However, future exercise could lead to dilution.
• Employees: This filing specifically relates to an executive, but executive compensation practices can influence overall company compensation philosophy and employee morale.

Next Steps

• The options will begin vesting on May 23, 2026, with subsequent monthly vesting installments over the following three years.

Key Dates

Keywords

Precigen, PGEN, Stock Options, SEC Form 4, Insider Transaction, Executive Compensation, Derivative Securities, Rutul R. Shah, Chief Operating Officer